Cargando…
SAT-LB18 A Randomized Controlled Trial of Vosoritide in Children With Achondroplasia
Background: Achondroplasia is a disorder caused by specific mutations in the gene encoding the fibroblast growth factor receptor 3 (FGFR3) protein. Open-label, phase 2 trials in children with achondroplasia showed that administration of vosoritide, an analogue of C-natriuretic peptide, resulted in s...
Autores principales: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7209563/ http://dx.doi.org/10.1210/jendso/bvaa046.2081 |
_version_ | 1783531107596107776 |
---|---|
author | Savarirayan, Ravi Tofts, Louise Irving, Melita Wilcox, William Bacino, Carlos A Hoover-Fong, Julie Font, Rosendo Ullot Harmatz, Paul Rutsch, Frank Bober, Michael B Polgreen, Lynda E Ginebreda, Ignacio Mohnike, Klaus Charrow, Joel Hoernschmeyer, Daniel Ozono, Keiichi Alanay, Yasemin Arundel, Paul Kagami, Shoji Yasui, Natsuo White, Klane Saal, Howard M Leiva-Gea, Antonio Luna-Gonzáles, Felipe Mochizuki, Hiroshi Basel, Donald Porco, Dania M Jayaram, Kala Fisheleva, Elena Huntsman-Labed, Alice Day, Jonathan |
author_facet | Savarirayan, Ravi Tofts, Louise Irving, Melita Wilcox, William Bacino, Carlos A Hoover-Fong, Julie Font, Rosendo Ullot Harmatz, Paul Rutsch, Frank Bober, Michael B Polgreen, Lynda E Ginebreda, Ignacio Mohnike, Klaus Charrow, Joel Hoernschmeyer, Daniel Ozono, Keiichi Alanay, Yasemin Arundel, Paul Kagami, Shoji Yasui, Natsuo White, Klane Saal, Howard M Leiva-Gea, Antonio Luna-Gonzáles, Felipe Mochizuki, Hiroshi Basel, Donald Porco, Dania M Jayaram, Kala Fisheleva, Elena Huntsman-Labed, Alice Day, Jonathan |
author_sort | Savarirayan, Ravi |
collection | PubMed |
description | Background: Achondroplasia is a disorder caused by specific mutations in the gene encoding the fibroblast growth factor receptor 3 (FGFR3) protein. Open-label, phase 2 trials in children with achondroplasia showed that administration of vosoritide, an analogue of C-natriuretic peptide, resulted in sustained increases in annualized growth velocity. Methods: This international, randomized, double-blind, phase 3 trial compared once-daily subcutaneous administration of vosoritide, at a dose of 15 μg per kg of body weight, with placebo in children with achondroplasia aged 5 to <18 years. Eligible patients had participated, for at least 6 months, in an observational growth study in order to calculate their baseline annualized growth velocity. The primary efficacy endpoint was the change from baseline in annualized growth velocity at week 52 of treatment. The primary analysis of the change from baseline in annualized growth velocity was performed using an ANCOVA model. Results: A total of 121 patients were randomized, with 60 assigned to receive vosoritide and 61 to receive placebo. A total of 119 patients completed the 52-week trial. The adjusted mean difference in annualized growth velocity between patients administered vosoritide and those administered placebo was 1.57 cm per year in favor of vosoritide (95% CI: [1.22, 1.93], two-sided p-value <0.001). A total of 119 patients experienced at least one adverse event (vosoritide group, 59 [98.3%], placebo group, 60 [98.4%]). Conclusions: Daily, subcutaneous administration of vosoritide to children with achondroplasia resulted in a significant increase in mean annualized growth velocity and similar incidence of adverse events compared to placebo. |
format | Online Article Text |
id | pubmed-7209563 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Oxford University Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-72095632020-05-13 SAT-LB18 A Randomized Controlled Trial of Vosoritide in Children With Achondroplasia Savarirayan, Ravi Tofts, Louise Irving, Melita Wilcox, William Bacino, Carlos A Hoover-Fong, Julie Font, Rosendo Ullot Harmatz, Paul Rutsch, Frank Bober, Michael B Polgreen, Lynda E Ginebreda, Ignacio Mohnike, Klaus Charrow, Joel Hoernschmeyer, Daniel Ozono, Keiichi Alanay, Yasemin Arundel, Paul Kagami, Shoji Yasui, Natsuo White, Klane Saal, Howard M Leiva-Gea, Antonio Luna-Gonzáles, Felipe Mochizuki, Hiroshi Basel, Donald Porco, Dania M Jayaram, Kala Fisheleva, Elena Huntsman-Labed, Alice Day, Jonathan J Endocr Soc Pediatric Endocrinology Background: Achondroplasia is a disorder caused by specific mutations in the gene encoding the fibroblast growth factor receptor 3 (FGFR3) protein. Open-label, phase 2 trials in children with achondroplasia showed that administration of vosoritide, an analogue of C-natriuretic peptide, resulted in sustained increases in annualized growth velocity. Methods: This international, randomized, double-blind, phase 3 trial compared once-daily subcutaneous administration of vosoritide, at a dose of 15 μg per kg of body weight, with placebo in children with achondroplasia aged 5 to <18 years. Eligible patients had participated, for at least 6 months, in an observational growth study in order to calculate their baseline annualized growth velocity. The primary efficacy endpoint was the change from baseline in annualized growth velocity at week 52 of treatment. The primary analysis of the change from baseline in annualized growth velocity was performed using an ANCOVA model. Results: A total of 121 patients were randomized, with 60 assigned to receive vosoritide and 61 to receive placebo. A total of 119 patients completed the 52-week trial. The adjusted mean difference in annualized growth velocity between patients administered vosoritide and those administered placebo was 1.57 cm per year in favor of vosoritide (95% CI: [1.22, 1.93], two-sided p-value <0.001). A total of 119 patients experienced at least one adverse event (vosoritide group, 59 [98.3%], placebo group, 60 [98.4%]). Conclusions: Daily, subcutaneous administration of vosoritide to children with achondroplasia resulted in a significant increase in mean annualized growth velocity and similar incidence of adverse events compared to placebo. Oxford University Press 2020-05-08 /pmc/articles/PMC7209563/ http://dx.doi.org/10.1210/jendso/bvaa046.2081 Text en © Endocrine Society 2020. http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (http://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com |
spellingShingle | Pediatric Endocrinology Savarirayan, Ravi Tofts, Louise Irving, Melita Wilcox, William Bacino, Carlos A Hoover-Fong, Julie Font, Rosendo Ullot Harmatz, Paul Rutsch, Frank Bober, Michael B Polgreen, Lynda E Ginebreda, Ignacio Mohnike, Klaus Charrow, Joel Hoernschmeyer, Daniel Ozono, Keiichi Alanay, Yasemin Arundel, Paul Kagami, Shoji Yasui, Natsuo White, Klane Saal, Howard M Leiva-Gea, Antonio Luna-Gonzáles, Felipe Mochizuki, Hiroshi Basel, Donald Porco, Dania M Jayaram, Kala Fisheleva, Elena Huntsman-Labed, Alice Day, Jonathan SAT-LB18 A Randomized Controlled Trial of Vosoritide in Children With Achondroplasia |
title | SAT-LB18 A Randomized Controlled Trial of Vosoritide in Children With Achondroplasia |
title_full | SAT-LB18 A Randomized Controlled Trial of Vosoritide in Children With Achondroplasia |
title_fullStr | SAT-LB18 A Randomized Controlled Trial of Vosoritide in Children With Achondroplasia |
title_full_unstemmed | SAT-LB18 A Randomized Controlled Trial of Vosoritide in Children With Achondroplasia |
title_short | SAT-LB18 A Randomized Controlled Trial of Vosoritide in Children With Achondroplasia |
title_sort | sat-lb18 a randomized controlled trial of vosoritide in children with achondroplasia |
topic | Pediatric Endocrinology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7209563/ http://dx.doi.org/10.1210/jendso/bvaa046.2081 |
work_keys_str_mv | AT savarirayanravi satlb18arandomizedcontrolledtrialofvosoritideinchildrenwithachondroplasia AT toftslouise satlb18arandomizedcontrolledtrialofvosoritideinchildrenwithachondroplasia AT irvingmelita satlb18arandomizedcontrolledtrialofvosoritideinchildrenwithachondroplasia AT wilcoxwilliam satlb18arandomizedcontrolledtrialofvosoritideinchildrenwithachondroplasia AT bacinocarlosa satlb18arandomizedcontrolledtrialofvosoritideinchildrenwithachondroplasia AT hooverfongjulie satlb18arandomizedcontrolledtrialofvosoritideinchildrenwithachondroplasia AT fontrosendoullot satlb18arandomizedcontrolledtrialofvosoritideinchildrenwithachondroplasia AT harmatzpaul satlb18arandomizedcontrolledtrialofvosoritideinchildrenwithachondroplasia AT rutschfrank satlb18arandomizedcontrolledtrialofvosoritideinchildrenwithachondroplasia AT bobermichaelb satlb18arandomizedcontrolledtrialofvosoritideinchildrenwithachondroplasia AT polgreenlyndae satlb18arandomizedcontrolledtrialofvosoritideinchildrenwithachondroplasia AT ginebredaignacio satlb18arandomizedcontrolledtrialofvosoritideinchildrenwithachondroplasia AT mohnikeklaus satlb18arandomizedcontrolledtrialofvosoritideinchildrenwithachondroplasia AT charrowjoel satlb18arandomizedcontrolledtrialofvosoritideinchildrenwithachondroplasia AT hoernschmeyerdaniel satlb18arandomizedcontrolledtrialofvosoritideinchildrenwithachondroplasia AT ozonokeiichi satlb18arandomizedcontrolledtrialofvosoritideinchildrenwithachondroplasia AT alanayyasemin satlb18arandomizedcontrolledtrialofvosoritideinchildrenwithachondroplasia AT arundelpaul satlb18arandomizedcontrolledtrialofvosoritideinchildrenwithachondroplasia AT kagamishoji satlb18arandomizedcontrolledtrialofvosoritideinchildrenwithachondroplasia AT yasuinatsuo satlb18arandomizedcontrolledtrialofvosoritideinchildrenwithachondroplasia AT whiteklane satlb18arandomizedcontrolledtrialofvosoritideinchildrenwithachondroplasia AT saalhowardm satlb18arandomizedcontrolledtrialofvosoritideinchildrenwithachondroplasia AT leivageaantonio satlb18arandomizedcontrolledtrialofvosoritideinchildrenwithachondroplasia AT lunagonzalesfelipe satlb18arandomizedcontrolledtrialofvosoritideinchildrenwithachondroplasia AT mochizukihiroshi satlb18arandomizedcontrolledtrialofvosoritideinchildrenwithachondroplasia AT baseldonald satlb18arandomizedcontrolledtrialofvosoritideinchildrenwithachondroplasia AT porcodaniam satlb18arandomizedcontrolledtrialofvosoritideinchildrenwithachondroplasia AT jayaramkala satlb18arandomizedcontrolledtrialofvosoritideinchildrenwithachondroplasia AT fishelevaelena satlb18arandomizedcontrolledtrialofvosoritideinchildrenwithachondroplasia AT huntsmanlabedalice satlb18arandomizedcontrolledtrialofvosoritideinchildrenwithachondroplasia AT dayjonathan satlb18arandomizedcontrolledtrialofvosoritideinchildrenwithachondroplasia |